{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T22:56:29Z","timestamp":1772232989813,"version":"3.50.1"},"reference-count":35,"publisher":"FapUNIFESP (SciELO)","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Braz. J. Nephrol."],"abstract":"<jats:p>Resumo  Introdu\u00e7\u00e3o: Rituximabe (RTX) \u00e9 uma op\u00e7\u00e3o terap\u00eautica na s\u00edndrome nefr\u00f3tica (SN) idiop\u00e1tica pedi\u00e1trica de dif\u00edcil tratamento. Visamos avaliar efic\u00e1cia e seguran\u00e7a do uso de RTX nestes pacientes.  M\u00e9todo: Realizou-se estudo retrospectivo de todos os pacientes com SN idiop\u00e1tica tratados com RTX, em uma unidade de nefrologia pedi\u00e1trica de um hospital terci\u00e1rio. Dados demogr\u00e1ficos, antropom\u00e9tricos, cl\u00ednicos e anal\u00edticos foram coletados antes do tratamento e aos 6, 12 e 24 meses.  Resultados: Inclu\u00edmos 16 pacientes (11 do sexo masculino), com idade mediana (percentil 25\u201375, P25\u2013P75) de 2 (2,0\u20132,8) anos ao diagn\u00f3stico. Quinze eram sens\u00edveis a esteroides, e 1 resistente a esteroides e sens\u00edvel \u00e0 ciclosporina.A idade mediana na administra\u00e7\u00e3o do RTX foi 10 (6,3\u201314,0) anos. Durante um tempo mediano de acompanhamento de 2,5(1,0\u20133,0) anos, 6 (37,5%) pacientes alcan\u00e7aram remiss\u00e3o parcial e 7 (43,8%) n\u00e3o tiveram recidivas e n\u00e3o estavam tomando imunossupressor no acompanhamento aos 24 meses. Quanto \u00e0s complica\u00e7\u00f5es,1 paciente apresentou hipogamaglobulinemia persistente. Comparado ao per\u00edodo de12 meses anterior ao RTX, houve diminui\u00e7\u00e3o no n\u00famero mediano de recidivas em 6 e 12 meses [3 (3,0\u20134,0) vs 0 (0\u20130,8) e 0,50 (0\u20131,0), respectivamente; p = 0,001] e na dose di\u00e1ria de esteroides (mg\/kg\/dia) aos 6, 12 e 24 meses [0,29 (0,15\u20130,67) &gt;vs [0,10 (0,07\u20130,13); p = 0,001], [0,12 (0,05\u20130,22); p = 0,005] e [0,07 (0,04\u20130,18); p = 0,021], respectivamente. Houve tamb\u00e9m redu\u00e7\u00e3o na mediana do escore z do IMC aos 24 meses [2,11 (0,45\u20133,70) vs 2,93 (2,01\u20133,98);p = 0,049].  Conclus\u00f5es: Nossos resultados confirmam a efic\u00e1cia e seguran\u00e7a do uso de RTX em SN idiop\u00e1tica pedi\u00e1trica, destacando seus potenciais benef\u00edcios cardiometab\u00f3licos.<\/jats:p>","DOI":"10.1590\/2175-8239-jbn-2022-0056pt","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T10:35:49Z","timestamp":1666002949000},"page":"326-334","source":"Crossref","is-referenced-by-count":2,"title":["Terapia com Rituximabe para s\u00edndrome nefr\u00f3tica idiop\u00e1tica de in\u00edcio na inf\u00e2ncia: experi\u00eancia de um centro terci\u00e1rio portugu\u00eas"],"prefix":"10.1590","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1246-194X","authenticated-orcid":false,"given":"Rita","family":"Gomes","sequence":"first","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio do Porto,  Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5474-7236","authenticated-orcid":false,"given":"Sara","family":"Mosca","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio do Porto,  Portugal"}]},{"given":"Mariana","family":"Bastos-Gomes","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade do Alto Minho,  Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-090X","authenticated-orcid":false,"given":"Liane","family":"Correia-Costa","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio do Porto,  Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1393-852X","authenticated-orcid":false,"given":"Liliana","family":"Rocha","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio do Porto,  Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5211-2467","authenticated-orcid":false,"given":"Ana","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio do Porto,  Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6478-4241","authenticated-orcid":false,"given":"Teresa","family":"Costa","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio do Porto,  Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8061-9289","authenticated-orcid":false,"given":"Maria","family":"Sameiro-Faria","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio do Porto,  Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1819-5275","authenticated-orcid":false,"given":"Paula","family":"Matos","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio do Porto,  Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4741-0002","authenticated-orcid":false,"given":"Concei\u00e7\u00e3o","family":"Mota","sequence":"additional","affiliation":[{"name":"Centro Hospitalar Universit\u00e1rio do Porto,  Portugal"}]}],"member":"530","published-online":{"date-parts":[[2023,9]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/17843286.2016.1208955","article-title":"Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature","volume":"72","author":"Van Horebeek I","year":"2017","journal-title":"Acta Clin Belgica Int J Clin Lab Med"},{"issue":"2","key":"ref2","first-page":"83","article-title":"Tratamiento con rituximab en pacientes pedi\u00e1tricos con s\u00edndrome nefr\u00f3tico c\u00f3rtico-dependiente","volume":"96","author":"Morais B","year":"2022","journal-title":"Experiencia en un hospital terciario. Pediatria (Napoli)"},{"issue":"9950","key":"ref3","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima K","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00467-018-4172-3","article-title":"Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome","volume":"34","author":"Maxted AP","year":"2019","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"ref5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","article-title":"Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome a randomized clinical trial","volume":"172","author":"Basu B","year":"2018","journal-title":"JAMA Pediatr"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2352-4642(18)30283-9","article-title":"Management of steroid-resistant nephrotic syndrome in children and adolescents","volume":"2","author":"Tullus K","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00467-017-3780-7","article-title":"Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options","volume":"33","author":"Kemper MJ","year":"2018","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13052-016-0271-6","article-title":"The efficacy and safety of rituximab in treating childhood nephrotic syndrome: an Italian perspective","volume":"42","author":"Maratea D","year":"2016","journal-title":"Ital J Pediatr"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00467-018-4166-1","article-title":"Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children","volume":"35","author":"Kamei K","year":"2020","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10157-016-1313-5","article-title":"Rituximab for nephrotic syndrome in children","volume":"21","author":"Iijima K","year":"2017","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00467-021-04983-3","article-title":"Update on the treatment of steroid-sensitive nephrotic syndrome","volume":"37","author":"Zotta F","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"ref12","first-page":"109","article-title":"Single dose of rituximab in children with steroid-dependent\/frequently relapsing nephrotic syndrome, clinical efficacy and evaluation of health-related quality of life","volume":"1","author":"Wang L","year":"2021","journal-title":"Iran J Kidney Dis"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","article-title":"Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes","volume":"97","author":"Chan EY","year":"2020","journal-title":"Kidney Int"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00467-009-1376-6","article-title":"Rituximab in refractory nephrotic syndrome","volume":"25","author":"Prytu\u0142a A","year":"2010","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00431-017-2891-2","article-title":"ESPN Working Group on Idiopathic Nephrotic Syndrome. Variability of diagnostic criteria and treatment of idiopathic nephrotic syndrome across European countries","volume":"176","author":"Desch\u00ea G","year":"2017","journal-title":"Eur J Pediatr"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","article-title":"Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome","volume":"27","author":"Kemper MJ","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00467-015-3245-9","article-title":"Cyclophosphamide and rituximab in frequently relapsing\/steroid-dependent nephrotic syndrome","volume":"31","author":"Webb H","year":"2016","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"ref18","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1681\/ASN.2014080799","article-title":"Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial","volume":"26","author":"Ravani P","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"ref19","first-page":"e13157","author":"Ahn YH","year":"2018"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin BH","year":"2021","journal-title":"Kidney Int"},{"issue":"2","key":"ref21","first-page":"70","article-title":"Rituximab use in children with complicated idiopathic nephrotic syndrome \u2013 a single centre experience","volume":"28","author":"Moreira CL","year":"2019","journal-title":"Nascer Crescer"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz GJ","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"46","key":"ref23","doi-asserted-by":"crossref","first-page":"e13157","DOI":"10.1097\/MD.0000000000013157","article-title":"Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea","volume":"97","author":"Ahn YH","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaut.2017.10.006","article-title":"NEPHRUTIX: A randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in Minimal Change Nephrotic Syndrome","volume":"88","author":"Boumediene A","year":"2018","journal-title":"J Autoimmun"},{"issue":"6","key":"ref25","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1681\/ASN.2021111472","article-title":"Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study","volume":"33","author":"Chan EY","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti P","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00467-018-4063-7","article-title":"Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study","volume":"34","author":"Takahashi T","year":"2019","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12882-019-1470-3","article-title":"Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial)","volume":"20","author":"Nagano C","year":"2019","journal-title":"BMC Nephrol"},{"issue":"9","key":"ref29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.medcli.2020.07.039","article-title":"Efficacy and safety of rituximab for childhood refractory nephrotic syndrome: a meta-analysis of randomized controlled trials","volume":"157","author":"Chang D","year":"2021","journal-title":"Med Clin (Barc)"},{"issue":"4","key":"ref30","article-title":"IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome","volume":"22","author":"Trautmann A","year":"2021","journal-title":"Nephrol Dial"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1681\/ASN.2011080775","article-title":"Rituximab in children with resistant idiopathic nephrotic syndrome","volume":"23","author":"Magnasco A","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"ref32","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1136\/archdischild-2020-321211","article-title":"Use of rituximab in paediatric nephrology","volume":"106","author":"Sinha R","year":"2021","journal-title":"Arch Dis Child"},{"issue":"10","key":"ref33","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1681\/ASN.2016101121","article-title":"Long-term outcome of steroid-resistant nephrotic syndrome in children","volume":"28","author":"Trautmann A","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/ndt\/gfu267","article-title":"Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome","volume":"30","author":"Sinha A","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"ref35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/archdischild-2019-318019","article-title":"Impact of rituximab on anthropometric indices among childhood steroid-dependent nephrotic syndromes","volume":"106","author":"Sinha R","year":"2021","journal-title":"Arch Dis Child"}],"container-title":["Brazilian Journal of Nephrology"],"original-title":["Rituximab therapy for childhood onset idiopathic nephrotic syndrome: experience of a Portuguese tertiary center"],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0101-28002023000300326&tlng=pt","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T07:21:18Z","timestamp":1697786478000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0101-28002023000300326&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["S0101-28002023000300326"],"URL":"https:\/\/doi.org\/10.1590\/2175-8239-jbn-2022-0056pt","relation":{"has-translation":[{"id-type":"doi","id":"10.1590\/2175-8239-jbn-2022-0056en","asserted-by":"subject"},{"id-type":"doi","id":"10.1590\/2175-8239-jbn-2022-0056en","asserted-by":"object"}]},"ISSN":["2175-8239","0101-2800"],"issn-type":[{"value":"2175-8239","type":"electronic"},{"value":"0101-2800","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}